Financial Consulate’s Sinovac Biotech, Ltd SVA Stock Holding History

Financial Consulate’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Hold	23	–	–	﹤0.01%	1533
2026 Q1	$0	Hold	23	–	–	﹤0.01%	1503
2025 Q4	$0	Hold	23	–	–	﹤0.01%	1461
2025 Q3	$0	Buy	+23	New	–	﹤0.01%	1154

Other funds holding SVA

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return

Horizon Investments Charlotte, North Carolina $9.13B AUM 34.49% 1-Year Est. Return

Financial Consulate's SVA Position: Q2 2026 in Review

Financial Consulate held its Sinovac Biotech, Ltd (SVA) position steady in Q2 2026 at 23 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1533.

Financial Consulate first reported a position in SVA in Q3 2025 and has held it in 4 quarters since. 29 funds tracked by Wall St. Rank hold SVA as of Q2 2026.

Financial Consulate held 23 shares of Sinovac Biotech, Ltd worth $0 as of Q2 2026.
Financial Consulate left its Sinovac Biotech, Ltd share count unchanged in Q2 2026.
Sinovac Biotech, Ltd made up ﹤0.01% of Financial Consulate's portfolio in Q2 2026, its #1533 holding.
Financial Consulate first reported a position in Sinovac Biotech, Ltd in Q3 2025 and has held it in 4 quarters since.
29 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.